Added to YB: 2026-10-09
Pitch date: 2026-10-04
OKUR [bullish]
OnKure Therapeutics, Inc.
-16.8%
current return
Author Info
No bio for this author
Company Info
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.
Market Cap
$99.6M
Pitch Price
$2.56
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.24
P/E
-0.95
EV/Sales
N/A
Sector
Biotechnology
Category
growth
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - OnKure Therapeutics, Inc.
OKUR (hold): OnKure is a precision-oncology company targeting PI3K-pathway biology with mutation-defined treatments that could fit a breast-cancer or broader solid-tumor franchise. Upside is meaningful if efficacy and tolerability data differentiate in the right genomic subset, but PI3K’s history of toxicity and inconsistent clinical translation means buyer urgency remains low; satellite sizing is appropriate until unusually clean patient-selection and safety evidence emerges.
Read full article (1 min)